

*This announcement contains inside information  
for the purposes of UK Market Abuse Regulation.*

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Notice of Results & Investor Presentations**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, will announce its full year results for the year ended 31 December 2024, on Tuesday 25 March 2025.

**Investor presentation**

Julian Baines, Executive Chair, and Stephen Young, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events, which are being held at different times to offer convenient options for those wishing to attend.

Two presentations will take place on Tuesday 25 March 2025 at the following times, the first will be held online via the Investor Meet Company platform and the second will be held in-person in the City of London, full details below:

**1. Investor Meet Company online presentation**

EKF management will provide a live online presentation relating to the final results via Investor Meet Company at 4.15pm on Tuesday 25 March 2025. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet EKF via:

<https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

**2. In-person investor presentation**

EKF management will provide an in-person presentation relating to the Company's final results at 5.30pm on Tuesday 25 March 2025, which is open to all existing and potential shareholders. The Company welcomes investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm start and will be followed by refreshments.

If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email [EKF@walbrookpr.com](mailto:EKF@walbrookpr.com).

**EKF Diagnostics Holdings plc**

Julian Baines, Executive Chair / Stephen Young, CFO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)

via Walbrook PR

**Singer Capital Markets (Nominated Adviser & Broker)**

Phil Davies / Oliver Platts

Tel: +44 (0)20 7496 3000

**Walbrook PR Limited**

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654





**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSSMFIEISELD